Benign Prostatic Hyperplasia Surgical Devices Market Growth Driven by High Incidence of Benign Prostatic Hyperplasia

 

The prostate gland is the prominent walnut-size gland that wraps around the urethra in a man. One of the most common diseases that affect the prostate is known as benign prostatic hyperplasia [BPH] or commonly referred to as enlarged prostate. Benign prostatic hyperplasia, when left untreated, can lead to urinary obstruction, blood in the urine, urethral enlargement or even cancer of the prostate.

High incidence of BPH is expected to aid in growth of the benign prostatic hyperplasia surgical devices market. The prevalence of histologically diagnosed BPH in the U.S. increases from 8% in men aged 31–40 years to over 80% in men older than age 80. The condition negatively impacts quality of life and results in considerable medical intervention and expenses.

BPH is a common problem among older men. According to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Thus, increasing geriatric population is expected to aid in growth of the growth of the benign prostatic hyperplasia surgical devices market. If you have mild BPH, then your doctor will recommend appropriate treatment. If you have moderate BPH or severe BPH, then your doctor will advise you to undergo surgery. However, do not immediately opt for surgery as a treatment. As discussed in the symptoms section, you may want to try an alternative treatment first before you resort to having a prostate surgery.

Players in the benign prostatic hyperplasia surgical devices market are focused on gaining reimbursement for various devices. In March 2021, Teleflex Incorporated announced that men suffering from BPH in France will now be offered a new minimally invasive treatment on the UroLift System, which is now reimbursable under French mandatory health insurance.

In March 2021, HTX Urology, a urology center in Webster, TX, U.S, participated in an FDA cleared research study for a new, minimally invasive device developed by Urotronic, Inc. a major player in the benign prostatic hyperplasia surgical devices market, for the treatment of BPH.

Noninvasive pulsed electromagnetic field therapy (PEMF) has demonstrated significant potential in the treatment of BPH. PEMF consists of low frequency pulsed energy waves and has been used for a variety of ailments such as various orthopedic conditions. Such developments are expected to aid in growth of the benign prostatic hyperplasia surgical devices market.